Tirzepatide Compounded

Is compounded tirzepatide still available?

Yes, within limits. Compounded tirzepatide is not FDA-approved, and with the shortage over it can no longer be produced as bulk copies of the brand. What remains is the patient-specific path: a licensed 503A pharmacy preparing it for an individual prescription where federal and state requirements are met, and that is how the telehealth programs tracked here offer it today. The FDA has proposed narrowing the large-scale side further, so availability can change.

What providers are offering right now

Every price is all-in: the monthly total with membership, shipping, and other required fees folded in, not an advertised starting rate. These figures come from each provider's own published pages, re-verified on a rolling schedule. The comparison list shows every plan behind them with its price, pharmacy source, and state availability.

Cost by dose, weekly injections

Most providers price by dose, so the monthly cost steps up as the dose does. Some charge one flat price at every dose instead. Each provider counts once per dose here, at its lowest all-in monthly price for that dose.

Oral and under-the-tongue formats run on their own daily schedules, so they are not in the weekly table. 6 providers offer them, running $148 to $299 a month all-in.

What changed, and when

• December 2024: the FDA declared the tirzepatide shortage resolved. During the shortage, federal law had allowed pharmacies to compound copies of the brand products.
• Early 2025: that shortage-era allowance ended on FDA wind-down deadlines: February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities.
• April 2026: the FDA proposed leaving tirzepatide, semaglutide, and liraglutide off the 503B bulks list, the list that would let outsourcing facilities keep compounding them at scale. The agency's stated reason: it found no clinical need for bulk compounding of these drugs.
• Right now: the proposal is not final. The FDA extended the public comment period to July 30, 2026, and a final decision comes after that. If it is finalized as written, bulk 503B compounding of tirzepatide ends, and patient-specific 503A compounding remains the lawful path.

503A and 503B, in plain terms

503A: a state-licensed pharmacy preparing medication for one named patient's prescription. This is the channel telehealth programs use, and it requires a documented clinical reason the FDA-approved product does not meet, such as a dose or formulation that is not commercially available or a sensitivity to an inactive ingredient.

503B: an FDA-registered outsourcing facility producing compounded medication in bulk batches. The FDA's current proposal targets this channel, not 503A.

What this means if you are comparing plans

Compounded plans are a pricing alternative to the brand versions, intended to contain the same active ingredient, though compounded versions are not FDA-approved or verified as equivalent. Two things on a provider's listing tell you the most: the pharmacy behind the plan and its 503A or 503B designation, both shown on each plan here when the provider discloses them.

This page is a general reference, not medical advice. Whether any medication or sourcing path fits your situation is a decision for you and a licensed prescriber.